#DNLI

Lead report

Denali expects $10M-$12M in Q3 AVLAYAH net product revenue as launch momentum builds (NASDAQ:DNLI)

Denali Therapeutics (DNLI) Q2 2026 earnings call highlights: AVLAYAH launch ramp, Q3 revenue guide $10–$12M, $1.1B cash, pipeline updates—read now.